MK-677 results: what to expect and when

• Early months: In the older-adult trial, daily MK-677 commonly increased appetite, while mild leg swelling and muscle pain were also reported.
• Within a few months: The trial reported that increased appetite faded within a few months for many participants.
• Month 12: Lean mass increased without better strength or function, and fasting blood sugar rose while insulin sensitivity fell in the older-adult trial.

An older-adult trial used 25 mg by mouth daily for one year, with a second year of follow-up treatment.

34 original human research records include case reports and ongoing trials; some share participants. Phase 3 is in children, with no results yet.

Key studies

• Older adults: lean mass and glucose: Lean mass increased, but strength and function did not improve. (source)
• Hip fracture: stopped over heart failure: Most function measures did not improve; heart-failure concerns ended the trial. (source)
• Earlier hip-fracture trial: Higher IGF-1 did not establish better recovery. (source)
• Alzheimer disease: no benefit: Raising IGF-1 did not slow Alzheimer disease. (source)
• Obese men: lean mass and glucose tolerance: The trial did not show fat loss and detected impaired glucose tolerance. (source)
• Obese men: bone turnover: Secondary hormonal or bone findings do not establish health benefits. (source)